Global Biosimilars Market Size Worth USD 130.1 Billion by 2035 | Roots Analysis

Biosimilars are highly similar versions of innovator biologics, which are developed after the originator product's patent expires. Biosimilars address critical healthcare needs through reduction in treatment costs by 20% to 50%, thereby enhancing patient access for those who may find these therapies financially burdensome. In addition, the biosimilars foster market competition by driving innovation in upcoming drugs and enhancing sustainability in the overall healthcare system by building on the existing knowledge / resources rather than designing entirely novel biologics. 

Moreover, streamlined regulatory frameworks have significantly contributed to the growing acceptance of biosimilars as an alternative to reference biologics. As the biopharmaceutical industry faces patent cliffs and pressure to reduce treatment costs, biosimilars are positioned to capture a revolutionary position in the global pharmaceutical market.

Key Report Takeaways

·         Presently, more than 900 biosimilars targeting a wide range of chronic diseases; of these, over 440 biosimilars are approved across the globe

·         Currently, over 170 players are engaged in the development of biosimilars; of these, more than 60% of players are headquartered in Asia-Pacific

·         The global biosimilars market is anticipated to grow at an annualized rate (CAGR) of 16.6%, till 2035; Europe is expected to capture the majority share (~50%) of the market by 2035

Competitive Landscape of Global Biosimilars Market

The global biosimilars market landscape features more than 900 biosimilars developed by more than 170 drug developers, worldwide. The global biosimilars market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Further, majority of the companies in the biosimilars market are presently headquartered in Asia-Pacific.

Global Biosimilars Market Regional Outlook

Based on the geographical regions, the global biosimilars market can be segmented into five major regions, North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Europe is anticipated to capture the majority share of the global biosimilars market in 2025. Further, the biosimilars industry in North America is accounted to be the fastest-growing segment of the market. This is primarily due to the increased approval and acceptance of biosimilars as a cost-effective treatment for chronic diseases in the region.

Global Biosimilars Market Key Players

This report also includes profiles of key companies in the biosimilars market are Amgen Inc, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Dr. Reddy’s Laboratories, Eli Lilly, Fresenius Kabi, Intas Pharmaceuticals, Pfizer Inc, Sandoz, STADA, and Teva Pharmaceutical.

It is interesting to note that, in August 2024, Biocon Biologics signed a partnership with Janssen for launching Bmab 1200, a proposed biosimilar to Stelara, for the treatment of autoimmune diseases in Europe, the UK, Canada, and Japan. 

To get market data, market insights, financial statements and a comprehensive analysis of the please contact sales@rootsanalysis.com

Global Biosimilars Market Segments

Based on the research, Roots Analysis has segmented the global biosimilars market into Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players.

by Drug Class

·         Monoclonal Antibodies

·         Proteins

·         Peptides

·         Others

by Therapeutic Area

·         Oncological Disorders

·         Autoimmune and Inflammatory Disorders

·         Hematological Disorders

·         Metabolic Disorders

·         Other Disorders

by Type of Manufacturer

·         Contract Manufacturers

·         In-house Developers

by Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

by Geographical Regions

·         North America

·         Europe

·         Asia-Pacific

·         Middle East and North Africa

·         Latin America

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com